The Assessment of New Radiation Oncology Technologies and Treatments Radiation Oncology Register Pilot

ABSTRACT: Interventions: The Department of Health and Ageing has asked the Trans Tasman Radiation Oncology Group (TROG) to develop and pilot a radiation oncology register as part of the ANROTAT (TRP 11.A) project (http://www.ANZCTR.org.au/ACTRN12612000168853.aspx). The ARORP will include the development and testing of a set of data variables to capture demographics, diagnosis, staging, surgical treatments, quality of Life, follow-up and radiotherapy intervention related data. A cross sectional feedback survey of participating centre staff authorised to enter data into the ARORP will be undertaken to assess the feasibility of the collection of the data items in routine practice as well as the web-based registration, the user manual and the register in general. Data will be collected in two groups of patients; 1. Prospective ANROTAT (TRP 11.A) study participants at or after the first follow-up visit 2. Patients who are attending for their annual follow-up appointment (including ANROTAT (TRP 11.A) retrospective patients and NON-ANROTAT patients). The data will be collected from the patients medical records, reports, RT plans and from QoL Questionniares. Patients are to be within 60months of completion of RT treament on registration, therefore the year range of the information collected will be from 2006-2012. The study population are patients who have undergone; - Image Guided Radiation Therapy (IGRT) or non-IGRT in patient with intermediate risk prostate cancer - Intensity Modulated Radiation Therapy (IMRT) or 3DCRT in patients with prostate cancer (post-proctectomy) - IMRT or 3DCRT in patients with nasophargeal cancer - IMRT or 3DRT in patients with anal cancer. This project will be open for registering patients from December 2011 t Primary outcome(s): To assess the completeness and accuracy of the data collected using the online register system[End of project] Study Design: Duration: Cross-sectional;Selection: Defined population;Timing: Both

DISEASE(S): Cancer-bowel-anal,Intermediate Risk Prostate Caner,Cancer-prostate,Anal Cancer,Cancer-other Cancer Types,Nasopharyngeal Cancer,Prostate Cancer (post Prostatectomy)

PROVIDER: 2457886 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR